

Table F-10. Harms/adverse effects in studies of other medical interventions

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
Active tDCS stimulation		
Skin changes ^{83, 84}	1 (3/10)	30%
Amantadine		
Challenging behavior ⁹¹	1 (2/19)	10%
Insomnia ⁹¹	1 (4/19)	21%
Somnolence ⁹¹	1 (2/19)	10%
Bumetanide		
Hyperactivity ⁷⁷	1 (2/27)	7.4%
Buspirone (2.5 mg twice/day)		
Abnormal behavior ⁹⁹	1 (5/46)	9%
Affective disorder ⁹⁹	1 (8/46)	15%
Agitation/nervousness/restlessness ⁹⁹	1 (7/46)	13%
Anxiety ⁹⁹	1 (6/46)	11%
Appetite decrease ⁹⁹	1 (17/46)	31%
Appetite increase ⁹⁹	1 (11/46)	20%
Challenging behavior ⁹⁹	1 (33/46)	71.7%
Ear and labyrinth disorders ⁹⁹	1 (7/46)	13%
Epistaxis ⁹⁹	1 (4/46)	7%
Eye disorders ⁹⁹	1 (7/46)	13%
Vomiting ⁹⁹	1 (20/46)	37%
Diarrhea ⁹⁹	1 (18/46)	33%
Constipation ⁹⁹	1 (5/46)	9%
Hyperactivity ⁹⁹	1 (15/46)	28%
Immune system disorders ⁹⁹	1 (5/46)	9%
Cough ⁹⁹	1 (25/46)	46%
Congestion ⁹⁹	1 (21/46)	45.6%
Rhinorrhea ⁹⁹	1 (15/46)	28%
Pyrexia ⁹⁹	1 (31/46)	57%
Ear Infection ⁹⁹	1 (11/46)	20%
Upper respiratory tract infection ⁹⁹	1 (6/46)	11%
Nasopharyngitis ⁹⁹	1 (6/46)	11%
Insomnia ⁹⁹	1 (14/46)	30%
Musculoskeletal disorders ⁹⁹	1 (5/46)	9%
Skin changes ⁹⁹	1 (8/46)	15%
Sleep changes ⁹⁹	1 (14/46)	26%
Somnolence ⁹⁹	1 (7/46)	13%
Urinary changes ⁹⁹	1 (6/46)	11%
Buspirone (5 mg twice/day)		
Abnormal behavior ⁹⁹	1 (1/49)	16%
Affective disorder ⁹⁹	1 (7/49)	13%
Agitation/nervousness/restlessness ⁹⁹	1 (7/49)	13%
Anxiety ⁹⁹	1 (3/49)	5%
Appetite decrease ⁹⁹	1 (11/49)	20%
Appetite increase ⁹⁹	1 (16/49)	29%
Challenging behavior ⁹⁹	1 (29/49)	59%
Ear and labyrinth disorders ⁹⁹	1 (3/49)	5%
Epistaxis ⁹⁹	1 (3/49)	5%
Eye disorders ⁹⁹	1 (5/49)	9%
Vomiting ⁹⁹	1 (23/49)	42%
Diarrhea ⁹⁹	1 (22/49)	40%
Constipation ⁹⁹	1 (15/49)	27%
Hyperactivity ⁹⁹	1 (12/49)	22%
Immune system disorders ⁹⁹	1 (3/49)	5%
Cough ⁹⁹	1 (23/49)	42%
Congestion ⁹⁹	1 (24/49)	48.9%

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
Rhinorrhea ⁹⁹	1 (17/49)	31%
Pyrexia ⁹⁹	1 (24/49)	44%
Ear Infection ⁹⁹	1 (6/49)	11%
Upper respiratory tract infection ⁹⁹	1 (3/49)	5%
Nasopharyngitis ⁹⁹	1 (4/49)	7%
Insomnia ⁹⁹	1 (23/49)	46.9
Musculoskeletal disorders ⁹⁹	1 (2/49)	4%
Skin changes ⁹⁹	1 (8/49)	15%
Sleep changes ⁹⁹	1 (19/49)	35%
Somnolence ⁹⁹	1 (6/49)	11%
Urinary changes ⁹⁹	1 (7/49)	13%
Divalproex sodium		
Agitation/nervousness/restlessness ⁷⁵	1 (2/16)	12.5%
Infection/fever/cold/congestion symptoms ⁷⁵	1 (2/16)	12.5%
Insomnia ⁷⁵	1 (2/16)	12.5%
Skin changes ⁷⁵	1 (2/16)	12.5%
Urinary changes ⁷⁵	1 (2/16)	12.5%
Donepezil hydrochloride		
Challenging behavior ⁹⁰	1 (5/17)	29.4
Levetiracetam		
Challenging behavior ⁹³	1 (3/10)	10%-20%
Mecamylamine		
Appetite decrease ⁸⁸	1 (4/12)	33.3%
EPS/impaired movement ⁸⁸	1 (2/12)	16.7%
GI symptoms ⁸⁸	1 (9/12)	75%
Infection/fever/cold/congestion symptoms ⁸⁸	1 (9/12)	75%
Mental symptoms ⁸⁸	1 (6/12)	50%
Somnolence ⁸⁸	1 (5/12)	41.7%
Melatonin		
Appetite decrease ⁸²	1 (2/6)	35.3%
GI symptoms ⁸²	1 (4/6)	70.6%
Somnolence ⁸²	1 (4/6)	70.6%
Memantine		
Affective disorder ⁹⁷	1 (2/60)	3.3%
Agitation/nervousness/restlessness ⁹⁷	1 (4/60)	6.7%
Challenging behavior ⁹⁷	1 (10/60)	8.3%
Enuresis ⁹⁷	1 (2/60)	3.3%
GI symptoms ⁹⁷	1 (11/60)	1.7%-6.7%
Headache ⁹⁷	1 (3/60)	5%
Infection/fever/cold/congestion symptoms ⁹⁷	1 (30/60)	1.7%-10%
Insomnia ⁹⁷	1 (5/60)	1.7%-6.7%
Self-injurious behavior ⁹⁷	1 (2/60)	3.3%
N-acetylcysteine		
Agitation/nervousness/restlessness ⁸⁹	1 (3/14)	21.4%
Appetite decrease ⁸⁹	1 (2/14)	14.3%
Appetite increase ⁸⁹	1 (2/14)	14.3%
Asthma ⁹⁵	1 (1/34)	2.9%
Cysts – Unspecified ⁹⁵	1 (1/34)	2.9%
EPS/impaired movement ⁸⁹	1 (3/14)	21.4%
GI symptoms ^{89, 95}	2 (23/48)	26.5%100%
Infection/fever/cold/congestion symptoms ^{89, 95}	2 (20/48)	2.9%-28.6%
Skin changes ⁹⁵	1 (2/34)	5.9%

Harm/Adverse Event	N Studies Reporting Harm (# Participants With Harm/Total Participants)	Reported Rates Across Studies
Tetrahydrobiopterin		
Challenging behavior ⁸⁶	1 (4/20)	22%
Hyperactivity ⁸⁶	1 (2/20)	9%
Insomnia ⁸⁶	1 (2/20)	9%
Skin changes ⁸⁶	1 (2/20)	9%
Agitation/nervousness/restlessness ⁹⁴	1 (3/5)	60%
Sleeping problems ⁹⁴	1 (4/5)	80%
Steroid		
Challenging behavior ⁹²	1 (10/20)	50%
Cushingoid appearance ⁹²	1 (18/20)	90%
Hypertension ⁹²	1 (2/20)	10%
Regression ⁹²	1 (2/20)	10%
Sleep changes ⁹²	1 (2/20)	10%
Weight gain ⁹²	1 (19/20)	95%
Hyperbaric oxygen		
Barotrauma ⁷⁸	1 (11/29)	37.9%
Placebo		
Abnormal behavior ^{97, 99}	2 (11/107)	3.3%-16%
Affective disorder ⁹⁹	1 (4/47)	7%
Agitation/nervousness/restlessness ^{75, 89, 93, 94, 97, 99}	6 (56/117)	1.6%-18%
Anxiety ^{97, 99}	2 (5/107)	2%-6.6%
Appetite decrease ^{82, 88, 89, 99}	3 (26/80)	20%-62.5%
Appetite increase ⁹⁹	1 (11/47)	19%
Barotrauma ⁷⁸	1 (3/29)	10.3%
Challenging behavior ^{86, 91, 93, 97, 102}	5 (51/148)	4.9%-39%
Epistaxis ^{97, 99}	2 (9/107)	3.3%-12%
EPS/impaired movement ^{88, 89}	2 (5/23)	6.7%-25%
GI symptoms ^{80, 82, 86, 88, 89, 92, 97}	7 (45/141)	1.6%-87.5%
Vomiting ⁹⁹	1 (22/47)	39%
Diarrhea ⁹⁹	1 (20/47)	35%
Constipation ⁹⁹	1 (10/47)	18%
Headache ⁹⁷	1 (3/60)	4.9%
Hyperactivity ^{86, 99}	2 (19/69)	4%-32%
Infection/fever/cold/congestion symptoms ^{75, 88, 89, 97}	4 (50/94)	1.6%-75%
Insomnia ^{86, 93}	2 (5/32)	10%-17%
Cough ⁹⁹	1 (28/47)	49%
Congestion ⁹⁹	1 (27/47)	57.4%
Rhinorrhea ⁹⁹	1 (15/47)	26%
Pyrexia ⁹⁹	1 (29/47)	51%
Ear Infection ⁹⁹	1 (8/47)	14%
Upper respiratory tract infection ⁹⁹	1 (12/47)	21%
Nasopharyngitis ⁹⁹	1 (6/47)	11%
Insomnia ^{75, 88, 89, 97, 99}	5 (36/159)	1.8%-34%
Mental symptoms ⁸⁸	1 (4/8)	50%
Musculoskeletal disorders ⁹⁹	1 (5/47)	9%
Psychomotor hyperactivity ⁹⁷	1 (4/60)	6.6%
Repetitive behavior or language ⁸⁶	1 (2/22)	9%
Seizure ^{79, 86}	2 (2/37)	4.5%-6.7%
Skin changes ^{77, 80, 99}	3 (11/100)	3.7%-12%
Sleep changes ^{94, 99}	2(18/53)	23%-83%
Somnolence ^{75, 82, 88, 99}	4 (50/76)	25%-81.3%
Urinary changes ^{93, 99}	2 (8/57)	10%-12%

*Harms reported by more than one participant. GI=gastrointestinal; EPS=extrapyramidal